BTIG Maintains Buy on Xtant Medical Hldgs, Lowers Price Target to $1
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and lowers the price target from $1.5 to $1.
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and lowers the price target from $1.5 to $1.